share_log

Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $4

Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $4

Needham维持对Heron Therapeutics的买入,将目标股价下调至4美元
Benzinga ·  2023/11/15 07:49

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $5 to $4.

Needham分析师塞尔吉·贝兰格维持Heron Therapeutics(纳斯达克股票代码:HRTX)的买入,并将目标股价从5美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发